Related Experiment Video
Updated: Apr 24, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer
Adam G Sowalsky1, Zheng Xia2, Liguo Wang2
1Division of Hematology and Oncology, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
Unlabelled:
Men with metastatic prostate cancer who are treated with androgen deprivation therapies (ADT) usually relapse within 2 to 3 years with disease that is termed castration-resistant prostate cancer (CRPC). To identify the mechanism that drives these advanced tumors, paired-end RNA-sequencing (RNA-seq) was performed on a panel of CRPC bone marrow biopsy specimens. From this genome-wide approach, mutations were found in a series of genes with prostate cancer relevance, including AR, NCOR1, KDM3A, KDM4A, CHD1, SETD5, SETD7, INPP4B, RASGRP3, RASA1, TP53BP1, and CDH1, and a novel SND1:BRAF gene fusion. Among the most highly expressed transcripts were 10 noncoding RNAs (ncRNAs), including MALAT1 and PABPC1, which are involved in RNA processing. Notably, a high percentage of sequence reads mapped to introns, which were determined to be the result of incomplete splicing at canonical splice junctions. Using quantitative PCR (qPCR), a series of genes (AR, KLK2, KLK3, STEAP2, CPSF6, and CDK19) were confirmed to have a greater proportion of unspliced RNA in CRPC specimens than in normal prostate epithelium, untreated primary prostate cancer, and cultured prostate cancer cells. This inefficient coupling of transcription and mRNA splicing suggests an overall increase in transcription or defect in splicing.
Implications:
Inefficient splicing in advanced prostate cancer provides a selective advantage through effects on microRNA networks but may render tumors vulnerable to agents that suppress rate-limiting steps in splicing.
Insights
Advanced prostate cancer exhibits inefficient RNA splicing, potentially driven by increased transcription or splicing defects. This splicing issue may offer a survival advantage but also presents a vulnerability for targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Metastatic prostate cancer treated with androgen deprivation therapy (ADT) often progresses to castration-resistant prostate cancer (CRPC).
- Understanding the molecular mechanisms driving CRPC is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the molecular drivers of castration-resistant prostate cancer (CRPC) using advanced genomic techniques.
- To identify novel therapeutic vulnerabilities in advanced prostate cancer.
Main Methods:
- Paired-end RNA sequencing (RNA-seq) was performed on CRPC bone marrow biopsy specimens.
- Quantitative PCR (qPCR) was used to validate gene expression and splicing patterns.
- Analysis included identification of gene mutations, fusions, and noncoding RNA expression.
Main Results:
- Mutations in key prostate cancer genes (e.g., AR, TP53BP1) and a novel SND1:BRAF fusion were identified in CRPC.
- High expression of noncoding RNAs (ncRNAs) involved in RNA processing, such as MALAT1, was observed.
- A significant proportion of sequence reads mapped to introns, indicating inefficient mRNA splicing in CRPC specimens compared to normal or early-stage prostate cancer.
Conclusions:
- Inefficient splicing is a hallmark of advanced prostate cancer, potentially conferring a selective advantage.
- This splicing defect may impact microRNA networks and represents a potential therapeutic target for CRPC treatment.
Related Concept Videos
RNA Splicing
RNA-seq
Before the discovery of RNA-seq, microarray-based methods and Sanger sequencing were used for transcriptome analysis. However, while...
Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
MicroRNAs
MicroRNAs
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...

